VBIV VBI Vaccines Inc.

0.69
+0.05  (+8%)
Previous Close 0.64
Open 0.66
Price To Book 1.6
Market Cap 122,890,513
Shares 64,078,781
Volume 9,176,156
Short Ratio
Av. Daily Volume 3,333,386
Stock charts supplied by TradingView

NewsSee all news

  1. Brii Biosciences Expands Infectious Disease Pipeline

    Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases Company pipeline now includes up to 12 partnered assets, in addition to internal development

  2. VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

    - Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection - Two-part, dose-escalation study expected to enroll up to 65 patients - Initial data expected in

  3. VBI Vaccines to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the Company's abstract titled,

  4. VBI Vaccines Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Final patient visit completed in CONSTANT study of Sci-B-Vac®, on-track for top-line data expected early January 2020 Entered into collaboration with GSK to evaluate the combination of VBI-1901 with GSK's AS01B

  5. VBI Vaccines Announces Late-Breaker Oral Presentation at IDWeek 2019™

    VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company's abstract

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data to be presented at SNO meeting November 22, 2019.
VBI-1901
Recurrent glioblastoma multiforme (rGBM)
Phase 3 data met co-primary endpoints but missed key secondary endpoint.
Sci-B-Vac - PROTECT
Hepatitis B vaccine
Phase 2 trial to be initiated YE 2019.
VBI-1501
Congenital Cytomegalovirus (CMV)
Phase 3 data due January 2020.
Sci-B-Vac - CONSTANT
Hepatitis B vaccine
Phase 2 trial to be initiated 4Q 2019 with data due 2H 2020.
BRII-179 (VBI-2601)
Hepatitis B vaccine

Latest News

  1. Brii Biosciences Expands Infectious Disease Pipeline

    Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases Company pipeline now includes up to 12 partnered assets, in addition to internal development

  2. VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

    - Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection - Two-part, dose-escalation study expected to enroll up to 65 patients - Initial data expected in

  3. VBI Vaccines to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the Company's abstract titled,

  4. VBI Vaccines Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Final patient visit completed in CONSTANT study of Sci-B-Vac®, on-track for top-line data expected early January 2020 Entered into collaboration with GSK to evaluate the combination of VBI-1901 with GSK's AS01B

  5. VBI Vaccines Announces Late-Breaker Oral Presentation at IDWeek 2019™

    VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company's abstract

  6. VBI Vaccines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its

  7. VBI Vaccines Announces Pricing of $35 Million Public Offering

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the pricing of its

  8. VBI Vaccines Announces Proposed Public Offering of Common Shares

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an

  9. VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology